Launches REVAHALE, India’s first once-daily nebulised LAMA for COPD - Zydus Lifesciences Ltd

Code BSE: 532321 NSE:

Zydus launches REVAHALE, India’s first once-daily nebulised LAMA for COPD REVAHALETM is the first and only LAMA available in India that combines once-daily dosing with nebulized administration, offering a new treatment option for COPD patients who require nebulised therapy. Designed to provide sustained 24-hour bronchodilation with a single daily dose, REVAHALETM addresses important challenges associated with inhaler-dependent therapies, particularly among elderly patients and those with severe respiratory impairment.